Public Sector Pension Investment Board grew its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 61.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 142,385 shares of the medical research company's stock after purchasing an additional 54,267 shares during the quarter. Public Sector Pension Investment Board's holdings in Amgen were worth $58,824,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of AMGN. Global Retirement Partners LLC lifted its position in Amgen by 2.1% in the 3rd quarter. Global Retirement Partners LLC now owns 25,032 shares of the medical research company's stock valued at $10,551,000 after acquiring an additional 510 shares in the last quarter. Legacy Financial Group LLC bought a new position in Amgen during the 3rd quarter worth about $205,000. Cibc World Market Inc. increased its holdings in Amgen by 84.0% during the 3rd quarter. Cibc World Market Inc. now owns 120,866 shares of the medical research company's stock worth $50,946,000 after purchasing an additional 55,181 shares in the last quarter. Cullen Capital Management LLC acquired a new stake in shares of Amgen in the 3rd quarter valued at about $202,000. Finally, Ironwood Investment Counsel LLC raised its stake in shares of Amgen by 3.8% in the 3rd quarter. Ironwood Investment Counsel LLC now owns 21,608 shares of the medical research company's stock valued at $9,108,000 after purchasing an additional 799 shares during the period. 76.50% of the stock is owned by institutional investors.
Amgen Price Performance
Shares of AMGN opened at $443.89 on Thursday. The company has a market cap of $240.10 billion, a price-to-earnings ratio of 25.75, a PEG ratio of 3.19 and a beta of 0.43. Amgen Inc. has a 1-year low of $312.39 and a 1-year high of $483.99. The company's fifty day simple moving average is $428.15 and its 200 day simple moving average is $382.85. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60.
Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, beating analysts' consensus estimates of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm had revenue of $10.37 billion during the quarter, compared to analysts' expectations of $10.07 billion. During the same quarter last year, the company posted $5.64 earnings per share. The company's revenue for the quarter was up 8.5% compared to the same quarter last year. On average, research analysts forecast that Amgen Inc. will post 23.37 earnings per share for the current fiscal year.
Amgen Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Friday, November 20th. Amgen's payout ratio is 58.47%.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on the company. Citigroup upped their price objective on Amgen from $405.00 to $465.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 4th. Bank of America increased their price objective on shares of Amgen from $312.00 to $317.00 and gave the stock an "underperform" rating in a research note on Wednesday, August 5th. HSBC cut Amgen from a "buy" rating to a "hold" rating and decreased their price objective for the company from $445.00 to $425.00 in a report on Thursday, September 10th. Royal Bank Of Canada lifted their target price on Amgen from $430.00 to $470.00 and gave the company an "outperform" rating in a research report on Wednesday, November 4th. Finally, Wall Street Zen upgraded Amgen from a "hold" rating to a "buy" rating in a report on Sunday, October 18th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, Amgen presently has an average rating of "Hold" and an average target price of $425.69.
Check Out Our Latest Stock Report on Amgen
Amgen Company Profile
(
Free Report)
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company's medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.